Hazard
45 recalls in our database tag this hazard, drawn from FDA, USDA FSIS, CPSC, and NHTSA source notices.
Of the 45 content uniformity recalls we have scored against our rubric, 4 (9%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 6 (13%) are Severe.
Hazard tags are short, machine-readable labels we attach to every recall to make cross-cutting queries possible — “all content uniformity recalls regardless of agency”, “all listeria recalls in California”, “all airbag recalls in 2025”. The tags are extracted from each recall’s source text during the LLM rewrite step and validated against a fixed schema.
A recall can carry multiple tags — a Listeria recall might also be tagged ready-to-eat and undeclared-allergen. Use the full-text search if you want to combine hazard tags with brand or category filters.
Lupin Pharmaceuticals is recalling Clobetasol Propionate Cream 0.05% because it failed content uniformity specifications. The recall covers 5,082 tubes distributed nationwide.
AvKARE is recalling 2,192 cartons of Norgestimate and Ethinyl Estradiol Tablets USP from one lot after the product failed content uniformity specifications.
Lupin Pharmaceuticals is recalling one lot of Cefixime oral suspension (200 mg/5 mL) due to failed content uniformity specifications. The recall affects 3,552 bottles distributed nationwide.
The FDA recalled Phenytoin Oral Suspension from Major Pharmaceuticals due to failed content uniformity specifications affecting 3,718 units distributed nationwide.
Sun Pharmaceutical recalls Dofetilide 500 mcg capsules nationwide due to out-of-specification results in content uniformity testing. Affected lot DNE0217A with expiration 01/2025 may not meet pharmaceutical specifications.
Sun Pharmaceutical is recalling 1,920 bottles of Dofetilide Capsules (500 mcg) nationwide due to failed content uniformity specifications, meaning the capsules do not contain uniform amounts of active ingredient.
Taro Pharmaceuticals recalls Clotrimazole and Betamethasone Dipropionate cream after a stability sample failed potency testing. The recall affects 768 tubes distributed to a retailer in New York, expiring June 2023. No illnesses have been reported.
Taro Pharmaceuticals is recalling specific lots of Clobetasol Propionate Cream 0.05% because the bulk material failed content uniformity testing.
Golden State Medical Supply Inc. is recalling specific lots of Clobetasol Propionate Cream, USP, 0.05% because the bulk material failed content uniformity testing.
Lupin Pharmaceuticals is recalling specific lots of oral contraceptive tablets due to failed content uniformity tests.
Lupin Pharmaceuticals is recalling specific lots of Bekyree oral contraceptives because they failed content and blend uniformity tests.
Macleods Pharma USA is recalling Telmisartan and Hydrochlorothiazide tablets because they failed content uniformity specifications for blend uniformity.
Westminster Pharmaceuticals is recalling specific lots of Levothyroxine and Liothyronine tablets because they failed content uniformity specifications due to an adulterated ingredient.
Westminster Pharmaceuticals is recalling Levothyroxine and Liothyronine tablets because they failed content uniformity specifications, potentially resulting in incorrect drug strength.
Westminster Pharmaceuticals is recalling Levothyroxine and Liothyronine tablets because they failed content uniformity specifications due to an adulterated ingredient and poor manufacturing controls.
Westminster Pharmaceuticals is recalling Levothyroxine and Liothyronine tablets because they failed content uniformity specifications due to an adulterated ingredient and poor manufacturing controls.
Lupin Pharmaceuticals is recalling Nitrofurantoin Oral Suspension because the drug is subpotent and failed content uniformity testing.
Taro Pharmaceuticals is recalling 27,792 tubes of Clobetasol Propionate Cream 0.05% because the product failed content uniformity specifications.
Taro Pharmaceuticals is recalling Nystatin and Triamcinolone Acetonide Cream because it failed content uniformity specifications during 18-month stability testing.
Virtus Pharmaceuticals is recalling 24,444 bottles of Hyoscyamine Sulfate tablets because they failed content uniformity specifications, resulting in inconsistent drug potency.
Virtus Pharmaceuticals is recalling Hyoscyamine Sulfate tablets because they failed content uniformity specifications, resulting in both superpotent and subpotent doses.
Virtus Pharmaceuticals is recalling Hyoscyamine Sulfate sublingual tablets because they failed content uniformity specifications, resulting in tablets that are either superpotent or subpotent.
Teva Pharmaceuticals USA is recalling Qnasl nasal aerosol because stability testing showed the product failed content uniformity specifications.
Teva Pharmaceuticals is recalling Qnasl nasal aerosol canisters because the product failed stability testing for spray content uniformity.
Nationwide Laboratories is recalling Salsalate Tablets, 750 mg, because they were manufactured under practices that may result in assay or content uniformity failures.